These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14762896)

  • 1. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC).
    Hayes S; Dunne A; Smart T; Davis J
    J Pharm Sci; 2004 Mar; 93(3):571-81. PubMed ID: 14762896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.
    González-García I; García-Arieta A; Merino-Sanjuan M; Mangas-Sanjuan V; Bermejo M
    Eur J Pharm Sci; 2018 Jul; 119():200-207. PubMed ID: 29680456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.
    Dunne A; O'Hara T; Devane J
    Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution specifications based on release rates.
    Elkoshi Z
    J Pharm Sci; 1999 Apr; 88(4):434-44. PubMed ID: 10187754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations.
    Uppoor VR
    J Control Release; 2001 May; 72(1-3):127-32. PubMed ID: 11389991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting dissolution specifications for modified-release dosage forms.
    Piscitelli DA; Young D
    Adv Exp Med Biol; 1997; 423():159-66. PubMed ID: 9269491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe.
    Limberg J; Potthast H
    Biopharm Drug Dispos; 2013 Jul; 34(5):247-53. PubMed ID: 23585295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between in vitro drug dissolution and in vivo response.
    Langguth P; Marroum P
    Biopharm Drug Dispos; 2012 Oct; 33(7):347-8. PubMed ID: 22910968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FIP Guidelines for Dissolution Testing of Solid Oral Products.
    Friedel HD; Brown CK; Barker AR; Buhse LF; Keitel S; Kraemer J; Morris JM; Reppas C; Sperry DC; Sakai-Kato K; Stickelmeyer MP; Shah VP
    J Pharm Sci; 2018 Dec; 107(12):2995-3002. PubMed ID: 30148985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence.
    Steinijans VW; Dietrich R; Trautmann H; Sauter R; Benedikt G
    Arzneimittelforschung; 1988 Aug; 38(8A):1238-40. PubMed ID: 3190812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.
    Gomez-Mantilla JD; Schaefer UF; Casabo VG; Lehr T; Lehr CM
    AAPS J; 2014 Jul; 16(4):791-801. PubMed ID: 24854895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of In Vitro-In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls.
    Kesisoglou F; Hermans A; Neu C; Yee KL; Palcza J; Miller J
    J Pharm Sci; 2015 Sep; 104(9):2913-22. PubMed ID: 25611455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling accelerated and decelerated drug release in terms of fractional release rate.
    Weiss M
    Eur J Pharm Sci; 2015 Feb; 68():51-5. PubMed ID: 25486334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inferential procedure for the probability of passing the USP dissolution test.
    Chiang C; Chen CF; Huang MY; Liu JP
    Pharm Stat; 2012; 11(1):32-8. PubMed ID: 21506255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.
    Karkossa F; Krueger A; Urbaniak J; Klein S
    AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.
    Qiu Y; Li X; Duan JZ
    J Pharm Sci; 2014 Feb; 103(2):507-16. PubMed ID: 24338862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated overview with simple and practical approach for developing in vitro-in vivo correlation.
    Jacob S; Nair AB
    Drug Dev Res; 2018 May; 79(3):97-110. PubMed ID: 29697151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.